Table 2

Patient’s clinical and treatment characteristics, intermediate cohort

Patient clinical and treatment characteristics
N, %
5801, 100
Patient clinical characteristics
Age
<501.698 (29.3)
50–642.503 (43.1)
≥651.600 (27.6)
AJCC stage*
Stage I2.843 (49.3)
Stage II2.368 (41.0)
Stage III558 (9.7)
Missing32
Molecular subtype†
HR+ HER2+603 (10.5)
HR+ HER2−4.409 (76.7)
HR− HER2+222 (3.8)
HR− HER2−516 (9.0)
Missing51
Grade
11.050 (18.3)
23.015 (52.4)
31.682 (29.3)
Missing54
Treatment characteristics
Surgery
None22 (0.4)
Breast conserving surgery4.223 (73.1)
Mastectomy1.532 (26.5)
Missing22
Axillary lymph node dissection
Sentinel lymph node biopsy3.443 (59.6)
Lymph node dissection2.334 (40.4)
Missing24
Adjuvant radiotherapy
No555 (9.6)
Yes5.212 (90.4)
Missing34
Neo/adjuvant chemotherapy
No2.691 (46.6)
Yes3.079 (53.4)
Missing31
Neo/adjuvant endocrine therapy
No1.134 (19.7)
Yes4.608 (80.3)
Missing59
Neo/adjuvant trastuzumab
No5.110 (88.7)
Yes650 (11.3)
Missing41
  • *According to AJCC (version 7),14 for patients treated with neoadjuvant therapy, we considered clinical stage; for all other patients, we considered pathological stage.

  • †HR and HER2 status, as abstracted from pathology reports. HR is considered positive if the estrogen receptor and/or progesterone receptor are positive. For HER2 classification, the fluorescence in situ hybridisation or IHC result was used. A positive result was considered if HER2 was amplified or IHC 3+.

  • AJCC, American Joint Committee on Cancer; HER2, human epidermal growth factor 2; HR, hormone receptor; IHC, immunohistochemistry.